DEN open · 2026
Efficacy and Safety of Remimazolam Compared to Midazolam for Sedation During Endoscopic Ultrasonography: A Single-Center Retrospective Cohort Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Toyonaga Haruka, Masaki Makoto, Yamazaki Hajime, Oka Arata, Matsuno Yoshiki, Nakata Hidetoshi, Takayama Shoji, Nakagawa Tatsuya, Takayama Takuya, Orino Masahiro, Matsumoto Hironao, Sumimoto Kimi, Takeo Masahiro, Fukata Norimasa, Yamashina Takeshi, Shimatani Masaaki, Naganuma Makoto
Аннотация
OBJECTIVES: Remimazolam is a novel ultra-short-acting benzodiazepine that may offer advantages over conventional sedatives in endoscopic procedures. Evidence for its use in pancreatobiliary endoscopic ultrasonography (EUS) is limited. We compared the efficacy and safety of remimazolam and midazolam in outpatient pancreatobiliary EUS.
METHODS: This retrospective study included outpatients undergoing diagnostic pancreatobiliary EUS between July 2024 and July 2025. Patients received either remimazolam (initial 0.2 mg/kg, top-up 0.1 mg/kg [high-risk patients: 0.16 mg/kg, 0.08 mg/kg]) or midazolam. The target sedation depth was Modified Observer's Assessment of Alertness/Sedation ≤3, procedures were performed without supplemental oxygen, and pentazocine was co-administered. The primary outcome was rapid recovery (meeting all criteria: modified Aldrete score ≥6 at 5 min, ≥9 at 30 min, ambulation ≥3 m at 30 min). Secondary outcomes included sedation success (all: EUS completion, without >2 top-ups within 10 min, without rescue sedation, without agitation requiring interruption), recovery time, flumazenil use, and adverse events.
RESULTS: We analyzed 139 patients (remimazolam, n = 75; midazolam, n = 64). Rapid recovery was more frequent with remimazolam (70.7% vs. 25.0%, p < 0.001). Sedation success was higher (92.0% vs. 73.4%, p = 0.005), recovery was shorter (median 34 vs. 55 min, p < 0.001), and flumazenil use was lower (4.0% vs. 45.3%, p < 0.001). Hypoxemia (SpO2 <90% lasting ≥10 s) occurred slightly more often with remimazolam (30.6% vs. 26.6%, p = 0.707), but all episodes were mild and reversible with airway support/oxygen. Hypotension was rare and comparable.
CONCLUSIONS: Remimazolam provided faster recovery and higher sedation success than midazolam in outpatient pancreatobiliary EUS. Supplemental oxygen before sedation is a reasonable option to enhance safety.
METHODS: This retrospective study included outpatients undergoing diagnostic pancreatobiliary EUS between July 2024 and July 2025. Patients received either remimazolam (initial 0.2 mg/kg, top-up 0.1 mg/kg [high-risk patients: 0.16 mg/kg, 0.08 mg/kg]) or midazolam. The target sedation depth was Modified Observer's Assessment of Alertness/Sedation ≤3, procedures were performed without supplemental oxygen, and pentazocine was co-administered. The primary outcome was rapid recovery (meeting all criteria: modified Aldrete score ≥6 at 5 min, ≥9 at 30 min, ambulation ≥3 m at 30 min). Secondary outcomes included sedation success (all: EUS completion, without >2 top-ups within 10 min, without rescue sedation, without agitation requiring interruption), recovery time, flumazenil use, and adverse events.
RESULTS: We analyzed 139 patients (remimazolam, n = 75; midazolam, n = 64). Rapid recovery was more frequent with remimazolam (70.7% vs. 25.0%, p < 0.001). Sedation success was higher (92.0% vs. 73.4%, p = 0.005), recovery was shorter (median 34 vs. 55 min, p < 0.001), and flumazenil use was lower (4.0% vs. 45.3%, p < 0.001). Hypoxemia (SpO2 <90% lasting ≥10 s) occurred slightly more often with remimazolam (30.6% vs. 26.6%, p = 0.707), but all episodes were mild and reversible with airway support/oxygen. Hypotension was rare and comparable.
CONCLUSIONS: Remimazolam provided faster recovery and higher sedation success than midazolam in outpatient pancreatobiliary EUS. Supplemental oxygen before sedation is a reasonable option to enhance safety.